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Abstract
Background: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL; apo2 ligand) induces apoptosis
in cancer cells but has little effect on normal cells. However, many cancer cell types are resistant to TRAIL-induced
apoptosis, limiting the clinical utility of TRAIL as an anti-cancer agent. We previously reported that the suppression
of adenine nucleotide translocase-2 (ANT2) by short-hairpin RNA (shRNA) induces apoptosis of breast cancer cells,
which frequently express high levels of ANT2. In the present study, we examined the effect of RNA shRNA-induced
suppression of ANT2 on the resistance of breast cancer cells to TRAIL-induced apoptosis in vitro and in vivo.
Results: ANT2 shRNA treatment sensitized MCF7, T47 D, and BT474 cells to TRAIL-induced apoptosis by up-
regulating the expression of TRAIL death receptors 4 and 5 (DR4 and DR5) and down-regulating the TRAIL decoy
receptor 2 (DcR2). In MCF7 cells, ANT2 knockdown activated the stress kinase c-Jun N-terminal kinase (JNK),
subsequently stabilizing and increasing the transcriptional activity of p53 by phosphorylating it at Thr81; it also
enhanced the expression and activity of DNA methyltransferase 1 (DNMT1). ANT2 shRNA-induced overexpression of
DR4/DR5 and TRAIL sensitization were blocked by a p53 inhibitor, suggesting that p53 activation plays an
important role in the transcriptional up-regulation of DR4/DR5. However, ANT2 knockdown also up-regulated DR4/
DR5 in the p53-mutant cell lines BT474 and T47 D. In MCF7 cells, ANT2 shRNA treatment led to DcR2 promoter
methylation and concomitant down-regulation of DcR2 expression, consistent with the observed activation of
DNMT1. Treatment of the cells with a demethylating agent or JNK inhibitor prevented the ANT2 shRNA-induced
down-regulation of DcR2 and activation of both p53 and DNMT1. In in vivo experiments using nude mice, ANT2
shRNA caused TRAIL-resistant MCF7 xenografts to undergo TRAIL-induced cell death, up-regulated DR4/DR5, and
down-regulated DcR2. Co-treatment with ANT2 shRNA and TRAIL efficiently suppressed tumor growth in these
mice.
Conclusions: ANT2 suppression by shRNA might be exploited to overcome TRAIL-resistance in cancer.
Background
Tumor necrosis factor (TNF)-related apoptosis-inducing
ligand (TRAIL; also known as apo2 ligand) is a member
of the TNF subfamily. TRAIL induces apoptosis by
recognizing and binding to its cognate receptors on cell
surfaces. These receptors are known as death receptor 4
(DR4; TRAIL receptor 1; TRAILR1) and death receptor
5 (DR5; TRAIL receptor 2; TRAILR2). Binding initiates
conformational changes in the receptors and recruits an
adaptor molecule (Fas-associated death domain) and
initiator caspases (caspase-8 and -10) to form a death-
inducing signaling complex. This process activates cas-
pase-8 and -10, which can then directly activate effector
caspases (caspase-3, -6, and -7) to cause apoptosis.
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protein to engage the intrinsic apoptotic pathway
through mitochondria. However, TRAIL can also bind
to decoy receptors 1 (DcR1; TRAILR3) and 2 (DcR2;
TRAILR4) on cell surfaces; these decoy receptors func-
tion as dominant-negative forms and protect cells from
apoptosis by competing with the death receptors for
TRAIL interaction [1,2].
Because TRAIL can induce apoptosis in cancer cells
but has little effect on normal cells, it is considered a
promising anticancer agent [1,2]. TRAIL-based thera-
pies, including recombinant human TRAIL and DR4/
DR5-specific agonistic monoclonal antibodies, are cur-
rently undergoing phase I and II clinical trials [3]. How-
ever, the anticancer applications of TRAIL are
unfortunately limited by the fact that cancer cells are
often resistant to TRAIL-induced cell death [4,5]. This
resistance is conferred by a number of molecular
changes, such as the reduced expression of death recep-
tors; the elevated expression of anti-apoptotic molecules,
including decoy receptors, FLICE-like inhibitory protein
(FLIP), X-linked inhibitors of apoptosis proteins
(XIAPs), anti-apoptotic Bcl-2-family proteins; and
NF-B activation [6,7]. Many efforts have been made to
identify strategies to overcome those TRAIL resistance
mechanisms. In fact, combination therapies using
recombinant TRAIL or agonistic anti-TRAIL receptor
monoclonal antibodies together with other anti-cancer
agents have shown improved efficacy for cancer treat-
ment in vitro and in vivo through modulation of
TRAIL-resistant mechanisms [7]. Some of the TRAIL-
sensitizing agents investigated have included histone
deacetylase inhibitors [8], cyclin-dependent kinase inhi-
bitors [9], proteasome inhibitors [10], Myc oncoproteins,
and Raf kinase inhibitor [11]. Several phytochemicals,
such as luteolin, also appear to be effective at overcom-
ing TRAIL-resistance via degradation of XIAP [12], and
3,3-diindolymethane down-regulates FLIP [13]. In addi-
tion, proteins of the Bcl-2 family, which are key regula-
tors of apoptosis through the intrinsic mitochondrial
pathway, are often deregulated in cancers and can be
manipulated to achieve TRAIL sensitization [14,15].
Adenine nucleotide translocase, a protein located in
the inner mitochondrial membrane, catalyzes the
exchange of mitochondrial ATP with cytosolic ADP and
participates in the formation of the mitochondrial per-
meability transition pore complex that interacts with
Bcl-2-family proteins. Adenine nucleotide translocase-2
(ANT2), one of the four adenine nucleotide translocase
isoforms expressed in humans, is expressed at high
levels in undifferentiated cells and tissues with high pro-
liferating and regenerating capacity, including lympho-
cytes, kidney, and liver [14-16]. Recently, ANT2 was
f o u n dt ob eo v e r - e x p r e s s e di nh o r m o n e - d e p e n d e n t
cancers, including breast and ovarian cancers [17]. The
induction of ANT2 in cancer cells is associated with gly-
colytic metabolism, suggesting a role for ANT2 in carci-
nogenesis [18-24].
We previously observed that the suppression of ANT2
by interference (RNAi) using vector-based short-hairpin
RNA (shRNA) disrupted the mitochondrial membrane
potential and induced apoptosis in human breast cancer
cells and that it inhibited tumor growth in an in vivo
xenograft model [16]. Moreover, suppression of ANT2
by shRNA modified the balance of Bcl-2 family proteins
in mitochondrial membranes to favor a pro-apoptotic
status [16]. These findings have led us to investigate the
therapeutic potential of ANT2 RNAi in combination
with TRAIL.
In the present study, we investigated the effect of
ANT2 shRNA treatment on TRAIL-resistant breast can-
cer cells. We found that it sensitized the cells to TRAIL,
greatly increasing their apoptotic response to TRAIL
in vitro and in vivo by up-regulating DR4 and DR5
expression and down-regulating DcR2 expression. These
effects were mediated by activation of c-Jun N-terminal
kinase (JNK), subsequent p53 activation, and DcR2 gene
methylation. Our results suggest that ANT2 shRNA
might be useful as a new TRAIL-sensitizing agent in
human breast cancer.
Methods
Cell lines and culture
The human breast cancer cell lines MCF7, MDA-
MB-231, T47 D, and BT474 were purchased from the
American Type Culture Collection (Manassas, VA,
U S A )a n dc u l t u r e di nD u l b e c c o ’s Modified Eagle Med-
ium supplemented with 10% fetal bovine serum,
100 units/ml penicillin, and 100 μg/ml streptomycin
(Gibco, Grand Island, NY, USA) in a humidified 5%
CO2/95% air atmosphere at 37°C.
Antibodies and reagents
Antibodies against human DR4 (TRAILR1), DR5
(TRAILR2), DcR1 (TRAILR3), and DcR2 (TRAILR4)
were purchased from R&D Systems (Minneapolis, MN,
USA). Antibodies against p53 and Thr81-phosphory-
lated p53 were from Santa Cruz Biotechnology (Hei-
delberg, Germany). Antibodies against JNK, phospho-
JNK, and b-actin were from Cell Signaling Technology
(Beverly, MA, USA). Antibodies against ANT2, poly
(ADP-ribose) polymerase (PARP), Bid, cleaved caspase-
8, cleaved caspase-9, cleaved caspase-7, cytochrome c,
DNA methyltransferase (DNMT1), and cyclooxygenase
(COX)-IV were from Abcam Inc (Cambridge, MA,
USA). Recombinant human TRAIL was purchased
from Peprotech Asia (Rocky Hills, NJ, USA) and the
methylation inhibitor 5-aza-2′-deoxycytidine (5-aza-dC)
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tor pifithrin-a was purchased from Biovision (Zürich,
Switzerland), and the JNK inhibitor SP600125 was
from Calbiochem-Novabiochem Corp (San Diego, CA,
USA).
Construction and transfection of ANT2 shRNA expression
vectors
The ANT2 shRNA expression vector used to achieve
specific down-regulation of ANT2 was described pre-
viously [16]. In brief, three kinds of ANT2 small-inter-
fering RNA (siRNA; namely, ANT2 siRNA-1, -2, and -3)
designed to be complementary to exon 2 or exon 4 of
ANT2 (GenBank accession number NM001152) were
synthesized, and DNA vectors expressing the shRNA
forms of the siRNAs were generated using pSilencer
3.1-H1 puro plasmids with a TTCAAGAGA linker
sequence that forms looped structures (Ambion, Austin,
TX, USA). The vector expressing ANT siRNA-1 oligo-
nucleotides (5′-GCAGAUCACUGCAGAUAAGTT-3′)
was used predominantly throughout this study. A
scrambled siRNA (Ambion) with no significant homol-
ogy to human gene sequences was used as a control to
detect nonspecific effects.
For transfection, cells were plated on six-well plates
(2 × 10
5 cells/well) or 100-mm dishes (2 × 10
6 cells/
dish) and allowed to adhere for 24 h. Lipofectamine
2000 (Invitrogen Corp., Carlsbad, CA) was used to
transfect cells with the pSilencer 3.1-H1 puro scrambled
siRNA vector (hearafter, scrambled shRNA) or pSilencer
3.1-H1 puro ANT2 siRNA vector (hearafter, ANT2
shRNA). After 6 h, the culture medium was replaced
with fresh complement medium, and the cells were har-
vested at 24-48 h after transfection. The pcDNA3.1 and
pcDNA3.1-ANT2 expression vectors were transfected
using a similar method.
Immunoblotting
Cells were lysed with lysis buffer [5 mM ethylenedia-
mine tetra acetic acid (EDTA), 300 mM NaCl, 0.1%
Nonidet P-40, 0.5 mM NaF, 0.5 mM Na3VO4,0 . 5m M
phenylmethylsulfonyl fluoride. and 10 μg/ml each
aprotinin, pepstatin, and leupeptin (Sigma)]. After cen-
trifugation at 15,000 × g for 30 min, the supernatant
fractions were analyzed for protein concentration using
Bradford reagent (Bio-Rad Laboratories, Inc., Hercules,
CA, USA). Aliquots containing 50-μg total protein
were subjected to electrophoresis in 10% SDS-PAGE
gels, transferred to polyvinylidene difluoride mem-
branes (Millipore, Bedford, MA, USA), and then incu-
bated with the appropriate antibodies. Immunoblots
were visualized using an enhanced chemiluminescence
detection system (Amersham Pharmacia Biotech,
Uppsala, Sweden).
Cell viability assay
Cell viability was measured using a CCK8 Cell Counting
Kit (Dojindo Molecular Technologies, Kumamoto,
Japan). Results of cell viability assays are presented as
the mean values of three replicate experiments per-
formed in triplicate.
Apoptosis assay [annexin V and propidium iodide (PI)
staining]
MCF7 cells at approximately 2 × 10
5 cells per ml were
transfected with ANT2 shRNA or scrambled shRNA for
the indicated lengths of time. The transfected cells were
harvested, washed twice with phosphate-buffered saline
(PBS), then incubated for 15 min at room temperature
with a solution of fluorescence isothiocyanate (FITC)-
conjugated annexin V (2.5 μg/ml) and PI (5 μg/ml) (BD
Pharmingen, San Diego, CA, USA), and analyzed for
apoptosis using flow cytometry (Epics XL; Coulter, Mar-
seille, France).
Reporter gene assay
A p53-luciferase-reporter construct containing many
p53 binding motifs was co-transfected with scrambled
or ANT2 shRNA into MCF7 cells using Lipofectamine
2000 (Invitrogen Corp.) and cultured for indicated
lengths of time. After the culture medium was removed,
the cells were rinsed gently with PBS, and 200 μl of lysis
buffer was added to each well. The cells were incubated
at 4°C for 15-20 min and then subjected to one freeze-
thaw cycle to ensure complete lysis. The cell lysates
were transferred to pre-labeled microcentrifuge tubes
and centrifuged at 12,000 × g for 4 min at 4°C. The
supernatant fractions containing the cell extracts were
recovered and assayed for luciferase activities using a
single-sample luminometer (FB12 luminometer; Bert-
hold Detection Systems, Pforzheim, Germany).
Methylation-specific PCR
Genomic DNA was obtained and purified using
QIAamp DNA mini Kits (Qiagen, Hilden, Germany).
The unmethylated cytosines in aliquots containing
500 ng DNA were converted to uracil using MethylCode
Bisulfite Conversion Kits (Invitrogen Corp.). We modi-
fied the manufacturer’s instructions by extending the
desulfonation step to 30 min to ensure complete con-
version of the genomic DNA and by pre-warming the
elution buffer to 50°C to increase the DNA yield.
Methylation-specific PCR for DcR2 was performed
using the primer pair 5′-TTGGGGATAAAGTGTTTT-
GATT-3′ (sense) and 5′-AAACCAACAACAAAAC-
CACA-3′ (antisense) for methylated DNA and the pair
5′-GGGATAAAGCGTTTCGATC-3′ (sense) and 5′-
CGACAACAAAACCGCG-3′ (antisense) for methylated
DNA. PCR mixtures contained 1× PCR buffer, 2 mM
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U/ml Taq polymerase, and 6 ng/ml converted DNA as
template. PCR products were resolved in 2% agarose
gels in 1× Tris/borate/EDTA buffer and stained with
ethidium bromide.
DNMT1 activity assay
Nuclear extracts from MCF7 cells transfected for 24 h
with ANT2 or scrambled shRNA (control) were evalu-
ated for DNMT1 activity using an EpiQuik Dnmt1
Assay Kit (Epigentek Inc., Brooklyn, NY, USA).
Animal experiments
To evaluate the anti-tumor effects of ANT2 shRNA and
TRAIL in vivo, we established tumor models in 6-8-
week-old BALB/c nude mice by subcutaneously injecting
5×1 0
6 MCF7 cells into their right flanks. Three weeks
after tumor inoculation, the mice began receiving intra-
peritoneal injections of PBS or TRAIL (10 mg/kg) with
or without intratumoral injections of scrambled shRNA
or ANT2 shRNA vector (100 μg; supplemented 200 μl
Lipofectamine 2000) thrice daily for 3 days. Tumor
dimensions were measured weekly using a caliper, and
tumor volumes were calculated using the formula m1
2 ×
m2 × 0.5236, where m1 and m2 represent the shortest
and longest tumor axes, respectively. At three weeks
after tumor challenge, the tumors were less than 300
mm
3 in volume. The mice were euthanized when
tumors reached 2 cm in diameter or became ulcerated;
at 45 days after tumor challenge, the tumor masses were
so large in the control and TRAIL groups that the mice
were euthanized.
Statistical analysis
Data were analyzed using the Student’s t test. Differ-
ences are considered statistically significant at P < 0.05.
Results
ANT2 suppression by shRNA sensitizes breast cancer cells
to TRAIL
We first examined the effect of TRAIL on the breast
cancer cell lines MCF7 and MDA-MB-231. In CCK8
cell viability assays, MDA-MB-231 cells, but not MCF7
cells, underwent cell death in response to TRAIL (Figure
1A); the MCF7 cells were strongly resistant to TRAIL
(Figure 1B). We previously reported that the specific
knockdown of ANT2 by RNAi using a DNA vector
expressing ANT2 shRNA could induce apoptosis of
breast cancer cells [16]. Therefore, to evaluate whether
ANT2 suppression increases the TRAIL sensitivity of
breast cancer cells, we treated the TRAIL-resistant
MCF7 cells with recombinant human TRAIL (100 ng/
ml) after transfecting then with ANT2 shRNA. As
shown in Figure 1B, transfection of ANT2 shRNA had a
slight cytotoxic effect, decreasing the viability of the
MCF7 cells by approximately 20%, but treatment of
ANT2 shRNA-transfected MCF7 cells with TRAIL
caused a much greater decrease in viability (about 70%)
than TRAIL or shRNA alone.
Morphologic evaluation of the cells for apoptosis
using annexin V/PI staining and flow cytometry con-
firmed that co-treatment with ANT2 shRNA and
TRAIL caused morphologic changes suggestive of apop-
tosis (Figure 1C) and increased the percentage of
annexin V or PI-positive cells (data not shown). The
TRAIL-resistant breast cancer cell lines T47 D and
BT474 also exhibited increased TRAIL sensitivity after
transfection with ANT2 shRNA (Figure 1D).
All RNAi experiments included an evaluation of the
effects of ANT2 and scrambled shRNA on ANT2
expression by RT-PCR (data not shown) and immuno-
blotting (Figure 1B). Treatment with the scrambled
shRNA control had no influence on TRAIL-induced
apoptosis in MCF7 cells, confirming the specific down-
regulation of ANT2 by ANT2 shRNA. Other shRNA
species directed to different regions of the ANT2
mRNA demonstrated similar TRAIL-sensitizing effects
(data not shown). To exclude the possibility of off-
target effects of ANT2 shRNA, we used a pcDNA
vector to restore ANT2 expression in MCF7 cells
transfected with ANT2 shRNA. As shown in Figure
1E, restoration of ANT2 expression reversed the
TRAIL-sensitizing effect of shRNA-induced ANT2
knockdown. These findings confirmed that the
observed ANT2 shRNA-induced sensitization of breast
cancer cells to TRAIL was caused by specific suppres-
sion of ANT2 rather than by unforeseen effects of
ANT2 shRNA on other genes.
To confirm that TRAIL-induced cell death in ANT2-
suppressed MCF7 cells occurs though an apoptotic
pathway, we evaluated the effects of ANT2 knockdown
and TRAIL on several molecules involved in apoptosis.
In immunoblot experiments, co-treatment with TRAIL
and ANT2 shRNA elicited caspase-8 and -9 activation,
cytochrome c release from mitochondria, and cleavage
of PARP (Figure 1F), consistent with induction of apop-
tosis. Although MCF7 cells are deficient in caspase-3,
they remain susceptible to cell death induced by several
stimuli including TNF, staurosporine, and various DNA-
damaging agents [17]. Consistent with a report that
other executive caspases, such as caspase-6 and -7, are
able to substitute for caspase 3 during apoptosis, co-
treatment with TRAIL and ANT2 shRNA elicited
caspase 7 activation in MCF7 cells (Figure 1F). These
findings suggest that TRAIL decreases the viability of
ANT2 shRNA-treated MCF7 breast cancer cells by
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caspase-7, -8, and -9 and involving the intrinsic mito-
chondrial apoptosis pathway.
ANT2 knockdown up-regulates death receptors and
down-regulates decoy receptors, thereby increasing the
TRAIL sensitivity of TRAIL-resistant breast cancer cells
Because TRAIL-resistance in certain cancer cell lines is
attributable to attenuated expression of the TRAIL
death receptors DR4 and DR5 or over-expression of the
decoy receptors DcR1 and DcR2, we examined the
expression of these receptors in various breast cancer
cell lines. TRAIL-resistant MCF7 cells were found to
express very low levels of pro-apoptotic DR4 and DR5
and a very high level of anti-apoptotic DcR2, whereas
TRAIL-sensitive MDA-MB-231 cells were found to
express high levels of DR4 and DR5 and a very low level
of DcR2 (Figure 2A). These data are consistent with
those previously reported [15].
These observations led us to assess the effects of
ANT2 shRNA transfection on the expression of TRAIL
receptors in MCF7 cells. As shown Figure 2B and 2C,
ANT2 knockdown dramatically increased DR4 and
DR5 expression and decreased DcR1 or DcR2 expres-
sion in MCF7 cells, as well as in the TRAIL-resistant
cell lines T47 D and BT474. These data suggested that
Figure 1 TRAIL cytotoxicity and expression of TRAIL receptors in the TRAIL-resistant breast cancer cell line MCF7 and the TRAIL-
sensitive breast cancer cell line MDA-MB-231. (A) Cell viability assays were performed 12 h after treatment of MCF7 and MDA-MB-231 cells
with recombinant human TRAIL. (B) MCF7 and MDA-MB-231 cells were transfected with 1 μg of scrambled or ANT2 shRNA. After 24 h, they were
treated with recombinant human TRAIL (100 ng/ml). Cell viability assays were performed 12 h after TRAIL treatment. (C) Morphologic analysis of
TRAIL-resistant MCF7 cells transfected with scrambled or ANT2 shRNA. After 24 h, the cells were treated with recombinant human TRAIL (100 ng/
ml) for 12 h and then examined under a phase contrast microscope. (D) The TRAIL-resistant cell lines T47 D and BT474 were treated with shRNA
and TRAIL and examined for cell viability as in (A). (E) MCF7 cells were transfected with scrambled or ANT2 shRNA. After 24 h, they were
transfected with pcDNA3.1 or pcDNA-ANT2. After another 24 h, they were treated with recombinant human TRAIL (100 ng/ml) for 12 h and
assayed for cell viability as in (B). (F) Immunoblot analysis of effect of ANT2 shRNA on TRAIL sensitivity. MCF7 cells were transfected with
scrambled or ANT2 shRNA, treated with TRAIL for 12 h as in (A). Cell extracts were prepared, subjected to SDS-PAGE, and immunoblotted with
antibodies as indicated.
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cells to TRAIL by shifting the expression of TRAIL
death and decoy receptors toward a pro-apoptotic
balance.
ANT2 knockdown up-regulates DR4 and DR5 expression
via activation of p53
Because the tumor suppressor protein p53 plays an
important role in regulating the expression of DR4 and
DR5 at the transcriptional level [25], we examined the
dependence of ANT2 knockdown-induced up-regulation
of DR4 and DR5 on p53 in MCF7 cells. Although
ANT2 knockdown did not affect the amount of p53
mRNA in the cells (data not shown), immunoblot analy-
sis revealed that it did increase the amounts of total and
Thr81-phosphorylated p53 protein (Figure 3A), consis-
tent with the up-regulation of DR4 and DR5 expression
(Figure 2B).
Reporter gene assays showed that ANT2 knockdown
resulted in the strong induction of p53 transcriptional
activity (Figure 3B). Furthermore, treatment with the
p53 inhibitor pifithrin-a not only prevented the up-reg-
ulation of DR4 and DR5 by ANT2 knockdown in MCF7
cells (Figure 3C) it also blocked its TRAIL-sensitizing
effect (Figure 3D). Taken together, these data suggest
that ANT2 shRNA treatment stabilizes p53 and
increases its transcriptional activity, thereby up-regulat-
ing DR4 and DR5 expression and priming TRAIL-resis-
tant MCF7 cells to undergo TRAIL-induced apoptosis.
ANT2 knockdown induces JNK activation
As shown in Figure 3A, we observed that ANT2
shRNA transfection increased the total amount of p53
protein and the amount of Thr81-phosphorylated p53
in MCF7 cells. Because JNK is known to specifically
phosphorylate p53 at Thr81 in response to stress, and
because JNK is important for p53 stabilization and
transcriptional activity [26], we hypothesized that JNK
might be activated by cellular stress (e.g., ATP deple-
tion) induced by ANT2 knockdown. As expected,
ANT2 shRNA treatment depleted ATP levels by
approximately half and was accompanied by JNK phos-
phorylation (Figure 4A and 4B). Furthermore, the
phosphorylation of p53 Thr81 in ANT2 shRNA-trans-
fected cells was inhibited by the JNK inhibitor
SP600125 (Figure 4C). Taken together, these findings
suggest that ANT2 knockdown activates JNK to stabi-
lize and activate p53, which then up-regulates DR4
and DR5 expression.
Through JNK activation, ANT2 knockdown induces
DNMT1 to hypermethylate the DcR2 promoter, thereby
down-regulating DcR2 expression
Our observation that ANT2 knockdown not only up-
regulated the expression of DR4 and DR5 but also
down-regulated the expression of DcR2 in MCF7 cells
led us to examine the methylation status of the DcR2
promoter. In MCF7 cells, the DcR2 promoter was lar-
gely unmethylated, but in ANT2 shRNA-transfected
MCF7 cells, the DcR2 promoter was hypermethylated,
thereby suppressing DcR2 expression (Figure 5A).
Furthermore, treatment with the demethylating agent
5-aza-dC restored DcR2 expression in ANT2-shRNA-
transfected MCF7 cells (Figure 5B). These data indi-
cate that DcR2 down-regulation in response to ANT2
knockdown is mediated by DcR2 promoter
hypermethylation.
DNMT1 catalyzes the methylation of CpG islands in
promoter regions, thereby contributing to gene silen-
cing. A report that DNMT1 activation is involved in
Figure 2 Effect of ANT2 shRNA on expression of TRAIL receptors in breast cancer cell lines. TRAIL receptor expression in MCF7 and MDA-
MB-231 cells (A), MCF7 cells transfected with scrambled or ANT2 shRNA for 24 h (B), and T47 D and BT474 cells transfected with scrambled or
ANT2 shRNA for 24 h (C) was analyzed by SDS-PAGE followed by immunoblotting of cell extracts with antibodies against DR4, DR5, DcR1, DcR2,
and b-actin (control) as indicated.
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knockdown activates JNK and causes hypermethyla-
tion of the DcR2 promoter in MCF7 cells, led us to
investigate the role of DNMT1 in ANT2 shRNA-
induced suppression of DcR2. Whiles DNMT1 protein
levels were significantly increased in MCF7 cells
transfected with ANT2 shRNA, this increase was
blocked by the JNK inhibitor SP600125 (Figure 5C).
Similarly, DNMT1 activity assays showed an
SP600125-inhibitable increase in DNMT1 activity in
MCF7 cells transfected with ANT2 shRNA (Figure
5D). SP600125 treatment also blocked the TRAIL-
sensitizing effect of ANT2 knockdown (Figure 5E).
T h e s ed a t as u g g e s tt h a tA N T 2k n o c k d o w n - i n d u c e d
JNK activation causes over-expression and activation
of DNMT1 in MCF7 cells, thereby inducing hyper-
methylation of the DcR2 promoter and subsequent
silencing of the DcR2 gene.
ANT2 knockdown increases TRAIL sensitivity of breast
cancer xenografts by regulating TRAIL receptors, thereby
significantly inhibiting tumor growth in vivo
Because our in vitro results suggested that ANT2 knock-
down enhances the apoptosis-inducing potential of
Figure 3 Up-regulation of DR4 and DR5 expression by ANT2 shRNA-induced activation of p53 in MCF7 cells. (A) Immunoblot analysis of
p53 expression and phosphorylation. MCF7 cells were transfected with scrambled shRNA or ANT2 shRNA. After 24 h, cells extracts were
prepared, subjected to SDS-PAGE, and immunoblotted with antibodies against phospho-p53, p53, a-tubulin, ANT2, and b-actin (control). Band
intensities were calculated using Image Gauge v4.0 (Fujifilm) (B) Reporter gene analysis of p53 transcriptional activity. MCF7 cells were
transfected with a p53-luciferase-reporter construct and scrambled or ANT2 shRNA. After 18 h, cell lysates were prepared and analyzed for
luciferase activities using a luminometer. (C) Immunoblot analysis of p53-mediated up-regulation of DR4/DR5. Cells were pre-treated with the
p53 inhibitor pifithrin-a for 2 h and then transfected with scrambled or ANT2 shRNA. After 24 h, cell lysates were prepared, subjected to SDS-
PAGE, and immunoblotted with antibodies against DR4, DR5, and a-tubulin. (D) Cells were treated with pifithrin-a and scrambled or ANT2
shRNA as in (C) and then analyzed for cell viability using a CCK8 assay kit.
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effects of ANT2 shRNA/TRAIL combination therapy on
a breast cancer xenograft model in vivo. For this pur-
pose, MCF7 cells were implanted into the right thighs
of BALB/c nude mice. Three weeks after implantation,
the mice began treatment with thrice daily injections of
PBS or TRAIL, with or without scrambled or ANT2
shRNA, for 3 days, as described in the Methods section.
The administration of TRAIL alone suppressed tumor
growth by approximately 15%, whereas the administra-
tion of ANT2 shRNA alone suppressed tumor growth
by approximately 65%. Of note, co-treatment with
ANT2 shRNA and TRAIL had a greater effect than
either treatment alone, inhibiting tumor growth by
approximately 90% (Figure 6A).
Treatment of the mice with ANT2 shRNA also up-
regulated DR4 and DR5 expression and down-regulated
DcR2 expression in the tumor cells (Figure 6B). These
findings suggest that the TRAIL-sensitizing effect of
ANT2 knockdown on breast cancer cells observed in
vitro also occurs in vivo via the same mechanism invol-
ving regulation of TRAIL receptors. Thus, combination
Figure 4 Transfection of ANT2 shRNA leads to JNK activation and subsequent up-regulation and activation of p53 in MCF7 cells.
(A) Analysis of ATP levels in lysates of MCF7 cells pre-treated with the JNK inhibitor SP600125 for 2 h and then transfected with scrambled or
ANT2 shRNA for 24 h. The data are shown in relative luminescence units (RLU) calculated by normalizing total intracellular ATP to total protein.
(B) MCF7 cells treated as in (A) were analyzed for JNK phosphorylation by immunoblotting using anti-phospho JNK and anti-JNK antibodies.
(C) Effect of JNK inhibition on ANT2 shRNA-mediated upregulation of DR4 and DR5. MCF7 cells were treated with SP600125 and scrambled or
ANT2 shRNA as in (A). Cell extracts were subjected to SDS-PAGE and immunoblotted with antibodies against phospho-p53, p53, DR4, DR5, and
b-actin (control).
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tive against breast cancer.
Discussion
The four known human ANT isoforms (ANT1, ANT2,
ANT3, and ANT4) exhibit tissue-, cell-type-, and devel-
opmental stage-specific expression patterns [18]. ANT1
is strongly expressed in terminally differentiated cells;
ANT2 is overexpressed in tissues that have high prolif-
erative ability and in several cancer cell lines [16,21]; and
ANT3 is ubiquitously expressed in all tissues. Whereas
ANT1 and ANT3 exert pro-apoptotic effects when over-
expressed, ANT2, instead, has an anti-apoptotic function
[20,28]. We previously observed that ANT2 is overex-
pressed in the breast cancer cell lines MCF7 and MDA-
MB-231 but is absent from the non-neoplastic mammary
Figure 5 ANT2 knockdown-induced JNK signaling up-regulates DNMT1, leading to methylation of the DcR2 promoter in MCF7 cells.
(A) Methylation-specific PCR analysis of effect of ANT2 shRNA on DcR2 genomic DNA of MCF7 cells. After cells were transfected with scrambled
or ANT2 shRNA for 24 h, they were lysed, and the genomic DNA was purified. Unmethylated cytosines were converted to uracils using an
Invitrogen MethylCode Bisulfite Conversion Kit, and the converted genomic DNA was used for PCR with methylation-specific primers. The cell
extracts were also analyzed for ANT2 and b-actin expression by immunoblotting. (B) RT-PCR analysis of the effect of ANT2 shRNA-induced
methylation on DcR2 expression. Cells were pre-treated with the methylation inhibitor 5-aza-dC for 2 h and then transfected with scrambled or
ANT2 shRNA. (C) RT-PCR analysis of effect of ANT2 shRNA-induced JNK signaling on DNMT1 expression. MCF7 cells were pre-treated with
SP600125 for 2 h and then transfected with scrambled or ANT2 shRNA. Cell extracts were also analyzed for DNMT1 and b-actin expression by
immunoblotting. (D) Effect of ANT2 shRNA-induced JNK signaling on DNMT1 activity. MCF7 cells were treated as in (C), and nuclear extracts
were evaluated for DNMT1 activity. (E) Effect of JNK inhibition on ANT2 shRNA-induced sensitization to TRAIL. MCF7 cells were treated with
SP600125 and scrambled or ANT2 shRNA as in (C), and 24 h after transfection, they were treated with recombinant human TRAIL (100 ng/ml) for
12 h. Cell viability was measured using a CCK8 assay kit.
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Page 9 of 12epithelial cell line MCF10A [16]. Moreover, vector-based
RNAi knockdown of ANT2 expression in MCF7 and
MDA-MB-231 cells resulted in cell cycle arrest and apop-
totic cell death; these events were accompanied by cellu-
lar energy (ATP) depletion, mitochondrial membrane
depolarization, Bax induction, and Bcl-xL down-regula-
tion [16]. TNF-a and TNF receptor I were also induced
through a bystander cytotoxic effect. Those data sug-
gested that suppression of ANT2 might selectively target
cancer cells while having little effect on normal cells.
Other researchers have also reported that ANT2 knock-
down sensitizes cancer cells to a chemotherapeutic agent
that targets mitochondria [21].
Apoptosis occurs via two main pathways, namely, the
extrinsic death receptor and intrinsic mitochondrial
pathways. Because TRAIL induces apoptosis selectively
in tumor cells, TRAIL-targeting agents are considered
promising candidates for cancer prevention and treat-
ment, but their clinical application is hindered by the
TRAIL-resistance of many cancer cells. Many kinds of
chemotherapeutic drugs or radiotherapy have been com-
bined with TRAIL-engaging agents to overcome TRAIL
resistance via various mechanisms [29-33]. Some of
these studies have presented convincing evidence that
up-regulation of the DR4 and DR5 death receptors and
down-regulation of the DcR1 and DcR2 decoy receptors
can restore the TRAIL sensitivity of TRAIL-resistant
cells [34-37]. In the present study, the resistance of
MCF7 cells to TRAIL-induced apoptosis led us to inves-
tigate whether ANT2 knockdown would sensitize these
cells to TRAIL. As has been previously reported [38],
we found that MCF7, but not MDA-MB-231 cells, were
strongly resistant to TRAIL-induced apoptosis. In line
with these observations, DR4 and DR5 expression was
low in MCF7 cells, and DcR2 expression was high,
whereas in TRAIL-sensitive MDA-MB-231 cells, DR4
and DR5 expression were strongly expressed and DcR2
expression was very low. Of note, ANT2 knockdown by
RNAi conferred TRAIL sensitivity on MCF7 cells by up-
regulating DR4/DR5 and down-regulating DcR2 in vitro
and in vivo. However, since ANT2 shRNA treatment
also affects the expression of Bax and Bcl-xL [16], the
ANT2 shRNA-induced sensitization of MCF7 cells to
TRAIL might involve alterations in the expression of
other molecules, such as FLIP, Bcl2-family proteins, and
XIAPs, that regulate TRAIL-mediated apoptosis.
JNK is activated by many cellular stresses, including
ultraviolet irradiation, oxidative stresses, inflammatory
cytokines, growth factor withdrawal, and DNA-damaging
agents (e.g., cisplatin, etoposide, and doxorubicin) [39].
JNK plays important roles in cell proliferation/survival and
apoptosis, and whether JNK activation results in cell pro-
liferation or apoptosis depends on the stimulus, the cell
type, the duration and strength of the activation signal,
and other factors [40]. JNK up-regulates pro-apoptotic
genes and down-regulates anti-apoptotic genes through
the transactivation of several transcription factors, includ-
ing c-Jun and p53 [40]. Our study is the first to character-
ize the effect of ANT2 on death receptor-mediated
apoptosis. We found that ANT2 knockdown activates JNK
and that this activation is indispensable for ANT2 shRNA-
induced sensitization of MCF7 cells to TRAIL. The activa-
tion of JNK led to phosphorylation of p53 at Thr81, the
consequent stabilization and transcriptional activation of
p53, and the previously well-characterized up-regulation
of DR4 and DR5 expression by activated p53.
Activation of JNK also induced DNMT1 expression in
ANT2 shRNA-treated MCF7 cells, although DNMT1
expression was not detected in untreated MCF7 cells.
This increased DNMT1 activity led to hypermethylation
of the DcR2 promoter, thereby suppressing DcR2 expres-
sion. Treatment of ANT2-knockdown MCF7 cells with a
JNK inhibitor prevented DNMT1 induction. The loss of
cellular energy (ATP) caused by ANT2 knockdown and
the resulting oxidative stress [41] might trigger JNK acti-
vation in order to stimulate apoptotic signaling.
Our experiments using a tumor xenograft model showed
that ANT2-knockdown-induced sensitization to TRAIL
also occurs in vivo a n dt h a tc o m b i n a t i o nt h e r a p yw i t h
ANT2 shRNA and TRAIL very efficiently inhibits tumor
growth. Our findings that the novel anti-cancer effects of
ANT2 knockdown in breast cancer cells involves TRAIL
Figure 6 Anti-tumor effects of ANT2 shRNA and TRAIL in a
breast cancer xenograft model in vivo. (A) Experimental protocol
for tumor challenge and shRNA and TRAIL treatment. BALB/c nude
mice were challenged with 5 × 10
6 MCF7 cells by subcutaneous
injection into the right flanks. After 21 days, they began 3 days of
treatment with thrice daily intraperitoneal injections of PBS or
human recombinant TRAIL with or without thrice daily intratumoral
injections of Lipofectamine 2000-supplemented scrambled or ANT2
shRNA vector. Calipers were used to make weekly measurements of
tumor dimensions, and tumor volumes were calculated as described
in the Methods. Measurements continued until day 45 after tumor
challenge. Data were analyzed using the Student t test. Differences
are considered statistically significant at P < 0.05. (B) Expression of
TRAIL receptors in tumors after shRNA and TRAIL treatment. Tumors
were isolated on day 45 after tumor challenge and subjected to RT-
PCR using primers specific for human DR4, DR5, DcR2, and GAPDH
(internal control).
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via JNK activation and subsequent increase of p53 activity
and DNMT1 expression suggest that ANT2 suppression
by shRNA might be useful as a new strategy for overcom-
ing TRAIL-resistance in cancer therapy.
Conclusions
Our findings suggest a new therapeutic strategy for
breast cancer. The use of ANT2 shRNA in combination
with TRAIL up-regulates DR4/DR5 expression and
down-regulates DcR2 expression in vitro and in vivo,
inducing apoptosis in a TRAIL-resistant human breast
cancer cell line and enhancing survival in a tumor-bear-
ing mouse model. Even by itself, ANT2 shRNA has an
anticancer effect in breast cancer cell lines, acting
through a mechanism involving the induction of p53
activity, JNK activation, DNMT1 expression, DR4/DR5
up-regulation, and DcR2 down-regulation, thereby mak-
ing the cells susceptible to TRAIL-induced apoptosis.
This study provides a foundation for the development of
combinatorial treatment regimens that enhance tumor
cell apoptosis. Furthermore, it shows that ANT2 shRNA
acts as a chemosensitizer when administered with
TRAIL, and that this chemosensitizing effect can over-
come TRAIL resistance in p53-wild-type cancers. How-
ever, DR4/DR5 up-regulation also occurs after ANT2
knockdown in the p53-mutant cell lines BT474 and T47
D, demonstrating that p53 is not a necessary component
of the ANT2-knockdown effect in these cells.
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